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Introduction: Although crizotinib manifests marked antitumor 
activity in individuals with non–small-cell lung cancer positive 
for ALK abnormalities, all treated patients ultimately develop 
resistance to this drug. The central nervous system (CNS) is a fre-
quent site of disease progression in such patients, with palliative 
radiotherapy usually being administered for the CNS metastasis. 
However, subsequent chemotherapy has not been optimized in 
these patients.
Methods: We retrospectively evaluated the continuation of crizotinib 
treatment after radiotherapy for isolated CNS progression in ALK-
rearrangement–positive non–small-cell lung cancer patients.
Results: Among 21 ALK-rearrangement–positive patients treated 
with crizotinib, seven individuals resumed daily crizotinib adminis-
tration after the completion of radiotherapy for isolated CNS failure. 
All these patients continued to receive crizotinib for at least 4 months 
after radiotherapy without disease progression. One patient expe-
rienced a recurrent isolated CNS failure during the second period 
of crizotinib administration but subsequently resumed crizotinib 
treatment again for at least 8.5 months after another application of 
radiotherapy.
Conclusions: Development of isolated CNS metastasis is emerging 
as a clinical concern for patients treated with crizotinib. Our data 
suggest that continued administration of crizotinib after radiotherapy 
for isolated CNS progression is a potential treatment option for such 
patients.
Key Words: Non–small-cell lung cancer, Crizotinib, Central nervous 
system, Metastasis.
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Recent insight into the molecular basis of non–small-cell lung cancer (NSCLC) has led to changes in the treatment 
of this disease. Fusion of the ALK gene and the EML4 gene 
occurs as the consequence of an inv(2)(p21p23) chromo-
somal translocation, resulting in production of the oncogenic 
fusion protein echinoderm microtubule-associated protein-
like 4-anaplastic lymphoma kinase (EML4-ALK) in approxi-
mately 5% of individuals with NSCLC.1–3
Crizotinib, an inhibitor of the tyrosine kinase activ-
ity of ALK, shows marked and durable antitumor activity 
in NSCLC patients who harbor EML4-ALK and other ALK 
abnormalities.4 Despite their initial response, however, such 
patients, treated with crizotinib, eventually develop systemic 
progression of disease, known as acquired resistance.5 The 
mechanisms of acquired resistance to crizotinib include muta-
tion at the gatekeeper site of the fusion protein or activation 
of bypass signaling.6 Other than systemic progression, iso-
lated central nervous system (CNS) failure, defined as a CNS 
relapse without progression at extracranial sites, is a common 
progression pattern in ALK–rearrangement–positive NSCLC 
patients treated with crizotinib.4,7 The most likely reason for 
such isolated CNS failure is incomplete penetration of the 
blood–brain barrier by crizotinib.8 Given that extracranial 
tumors in patients who develop isolated CNS failure are con-
sidered to remain sensitive to crizotinib, we have now retro-
spectively assessed the continuation of crizotinib treatment 
beyond CNS progression in ALK-rearrangement–positive 




Twenty-one individuals with recurrent or metastatic 
NSCLC positive for ALK rearrangement and were treated with 
crizotinib were identiﬁed through the electronic pharmacy 
record system at Kinki University Hospital (Japan), which 
includes the medication history of all treated patients. We 
included patients who continued to receive crizotinib after 
radiotherapy for the development of isolated CNS metastasis, 
including whole-brain radiotherapy (WBRT), stereotactic 
radiotherapy (SRT), or other surgery performed after 
consultation with neurosurgeons and radiation oncologists. 
Patient characteristics recorded included sex, age, tumor 
histology, disease stage, postoperative disease recurrence, 
smoking history, and prior chemotherapy. Written informed 
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consent was obtained from each patient before treatment with 
crizotinib.
Detection of ALK Rearrangement
ALK rearrangement was detected by fluorescence in situ 
hybridization analysis with formalin-fixed, paraffin-embed-
ded tumor tissue and break-apart probes for ALK (Vysis LSI 
ALK Dual Color, Break Apart Rearrangement Probe; Abbott 
Molecular, Abbott Park, IL). ALK–rearrangement–positive 
cases were defined as those with 15% or more of tumor cells 
showing split signals.
Treatment and Evaluation of Response
Patients received crizotinib (250 mg) twice a day 
orally. Treatment was interrupted during palliative radio-
therapy because it was terminated a day before and resumed 
a day after. Tumor response was evaluated according to the 
Response Evaluation Criteria in Solid Tumors version 1.1. 
Magnetic resonance imaging was performed to evaluate 
neurological symptoms and to detect any change in pre-
existing CNS disease. On detection of CNS progression, 
extracranial sites were also fully re-evaluated. An isolated 
CNS failure was defined as a CNS relapse without relapse at 
other sites or another type of treatment failure. Progression-
free survival for the first period of crizotinib administra-
tion was defined as the time from the start of the treatment 
to disease progression according to Response Evaluation 
Criteria in Solid Tumors 1.1, whereas that for second and 
third periods of crizotinib administration was defined as the 
time from the initiation of radiotherapy for isolated CNS 




Among 21 NSCLC patients positive for ALK rear-
rangement and treated with crizotinib in the present study, 13 
individuals discontinued treatment as a result of disease pro-
gression, including eight patients with isolated CNS metasta-
sis, one with metastases in both the CNS and other sites, and 
four with metastasis at non-CNS sites only. Among the eight 
patients with isolated CNS metastasis, one individual (case 8) 
discontinued treatment 1.6 months after initiation of crizotinib 
because of a deterioration in performance status associated 
with carcinomatous meningitis and did not resume crizo-
tinib treatment, whereas the remaining seven patients con-
tinued to receive crizotinib after radiotherapy for the isolated 
CNS metastasis. They included six women and seven light or 
never-smokers, and they all had adenocarcinoma histology. 
Their median age was 46 years, with a range of 23 to 66 years. 
Five of the patients experienced CNS metastasis before initial 
crizotinib treatment, including three with a single CNS lesion, 
and two with multiple (≥2) metastatic sites. Two of these five 
patients received SRT before initiation of crizotinib, whereas 
the remaining three patients were not treated with radiother-
apy as a result of physician choice.
Treatment Outcome and Subsequent 
Crizotinib Therapy after First Progression
Among the seven patients who developed isolated CNS 
metastasis and resumed crizotinib treatment after radiother-
apy, the median progression-free survival for the first period 
of crizotinib administration was 5.5 months, with a range of 
2.6 to 17.2 months (Fig. 1, Table 1). The pattern of isolated 
CNS failure included newly developed CNS metastasis in five 
patients (cases 1, 2, 3, 4, and 7) and regrowth of a pre-existing 
CNS lesion in two patients (cases 5 and 6). WBRT and SRT 
were performed for isolated CNS metastasis in four patients 
(cases 1, 2, 4, and 7) and three patients (cases 3, 5, and 6), 
respectively, and all patients resumed daily crizotinib treat-
ment after the completion of radiotherapy. Three patients con-
tinued to receive crizotinib for at least 4 months until disease 
progression at extracranial sites (cases 1, 3, and 4), whereas 
another three patients had continued crizotinib treatment for 
6.2, 7.5, and 5.1 months (cases 2, 6, and 7, respectively) at 
their last follow-up without CNS or extracranial relapse (Fig. 
1, Table 1). One patient (case 5) experienced a recurrent 
isolated CNS failure during the second period of crizotinib 
administration, but has now continued crizotinib treatment for 
8.5 months, with no evidence of disease progression after a 
second application of SRT.
DISCUSSION
The development of CNS metastasis is a common and 
serious complication of NSCLC, having an adverse impact 
on quality of life and survival.9 Pooled analyses of ALK-
rearrangement–positive patients enrolled in crizotinib trials 
have shown that the most common site of new lesions dur-
ing crizotinib treatment is the CNS.4,7 Once patients develop 
CNS metastasis, chemotherapy is usually terminated and pal-
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chemotherapy after radiation treatment has not been opti-
mized in such patients.
The present study retrospectively evaluated the 
clinical value of continuing crizotinib administration after 
radiotherapy for isolated CNS failure, without extracranial 
progression. A recent study found that the concentration of 
crizotinib is much lower in cerebrospinal ﬂuid (CSF) than 
in plasma,8 indicative of poor penetration of the blood–brain 
barrier by the drug. The CSF/plasma ratios for the epidermal 
growth factor receptor (EGFR)-tyrosine kinase inhibitors 
(TKIs), gefitinib and erlotinib, are similarly low,10,11 resulting 
in an increased likelihood of isolated CNS metastasis in 
patients with EGFR-mutation–positive advanced NSCLC, 
who are treated with these agents.12 Despite the improved 
control of extracranial disease achieved with EGFR-
TKIs and crizotinib, these drugs are unable to prevent the 
development of CNS metastasis as a result of their low CSF/
plasma ratios. Systemic disease progression (also known 
as acquired resistance) in patients receiving EGFR-TKIs or 
crizotinib occurs through several molecular mechanisms, 
including the acquisition of gatekeeper mutations in the 
corresponding tyrosine kinase, with the resistant patients 
not showing any response to continued TKI treatment. In 
contrast, extracranial tumors in patients who develop isolated 
CNS metastasis as a result of poor drug penetration of the 
blood–brain barrier (pharmacokinetic resistance) are likely to 
remain sensitive to these molecularly targeted therapies.10,11 
Indeed, resumption of daily administration of gefitinib after 
WBRT or SRT for isolated CNS failure in NSCLC patients 
was found to be effective for control of extracranial disease.13 
It thus seems reasonable to continue crizotinib administration 
for control of extracranial systemic disease in patients with 
ALK–rearrangement–positive NSCLC, who develop isolated 
CNS progression, but in whom the CNS metastasis is well 
controlled. In the present study, all patients, who were treated 
with radiotherapy for isolated CNS metastasis, successfully 
continued to receive crizotinib for at least 4 months. The entire 
treatment period from initiation of crizotinib to systemic 
disease progression in these patients was similar to that 
reported in a previous study of crizotinib therapy for ALK-
rearrangement–positive patients.4 Our results thus provide a 
practical strategy for treating ALK-rearrangement–positive 
patients who develop isolated CNS metastasis.
One patient (case 5) in the present study developed 
recurrent CNS progression during the second period of 
crizotinib treatment. The management of patients who show 
recurrent isolated CNS failure during crizotinib therapy is 
an emerging clinical problem. A therapeutic approach to 
overcome pharmacokinetic resistance to EGFR-TKIs in the 
CNS has been suggested by the observation that intermittent 
administration of high-dose erlotinib (1500 mg per week) was 
able to control CNS metastases that were resistant to continuous 
administration of normal-dose erlotinib (150 mg daily) in a 
patient with NSCLC.11 Therapeutic CSF concentrations of 
such agents might thus be achieved by administration of higher 
doses. High-dose crizotinib may, therefore, be an option for 
treatment of CNS metastasis in ALK-rearrangement–positive 
patients, although there are currently no data demonstrating 
the safety of such an approach. Novel strategies to enhance 
exposure of the CNS to ALK inhibitors, including the 
development of new such drugs with a greater ability to cross 
the blood–brain barrier are thus warranted.
In conclusion, our data suggest that continued admin-
istration of crizotinib after radiotherapy for isolated CNS 
progression is a potential treatment option for patients with 
ALK-rearrangement–positive NSCLC in whom the CNS 
metastasis is well controlled.
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during Crizotinib Treatment
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PFS for Third 
Crizotinib 
Administration (mo)
1 PR 7.6 CNS New lesion WBRT 4.8 Lung, CNS
2 CR 17.2 CNS New lesion WBRT 6.2 (Ongoing)
3 SD 4.1 CNS New lesion SRT 7.5 Lung
4 PR 4.9 CNS New lesion WBRT 4.4 Lung
5 PR 2.6 CNS Regrowth SRT 11.0 CNS 8.5 (Ongoing)
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8 PD 1.6 CNS New lesion None
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease, CNS, central nervous system; WBRT, whole-brain radiotherapy; SRT, stereotactic 
radiotherapy; PFS, progression-free survival, NSCLC, non–small-cell lung cancer.
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